NICE rejects use of cancer drug Tarceva
14th Nov 2006, 11:48 GMT
Tarceva, a lung cancer drug manufactured by Roche, may not be approved in the UK following a negative recommendation by the National Institute for Health and Clinical Excellence.
NICE rejects use of cancer drug Tarceva related news:
- NICE Rejects Use of Cancer Drug Tarceva — RedOrbit News - Health
- NICE disapproves the use of cancer drug Tarceva — The Earth Times Online Newspaper
- NICE consults on advice on two treatments for NSCLC — OnMedica Latest News
- NICE refuse to fund life-prolonging cancer drug available in Scotland — the Mail online | Health
- NICE refuses to fund life-prolonging cancer drug available in Scotland — the Mail online | Health
- Watchdog rules against new treatment for lung cancer — Guardian Unlimited UK Latest
- NICE refuses to fund £20,000 cancer drug available in Scotland — the Mail online | Home
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- Targeted cancer drugs may work by disrupting balance of cellular signals — EurekAlert! - Cancer
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol